Anika CEO exercises RSUs, gains stock award
Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units.
Rhea-AI Filing Summary
Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units. On March 14, 2026, he exercised 12,824 restricted stock units, receiving 12,824 shares of common stock at a stated exercise price of $0.00 per share.
On the same date, he also acquired 6,412 shares of common stock as a grant or award, and 5,944 shares were withheld by the company at $14.20 per share to cover tax obligations related to vested RSUs and PSUs. Following these transactions, Griffin directly owns 23,963 shares of Anika Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 12,824 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,824 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 6,412 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,944 | $14.20 | $84K |
Footnotes (4)
- F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
- F2. On March 14, 2025, the Reporting Person was granted 19,236 performance-based phantom RSUs ("PSUs") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award.
- F3. Reflects an aggregate of 5,944 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026.
- F4. On March 14, 2025, the Reporting Person was granted 38,473 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Anika Therapeutics (ANIK) report for CEO Stephen D. Griffin?
What performance-based and time-based equity awards are referenced in Anika (ANIK) CEO’s Form 4 footnotes?
AI-generated analysis. How Rhea-AI works. Not financial advice.